I believe this may be wrong in the PR since it is unknown what SOC will be used by the doctors. I think the 30 minute IV infusion weekly over a four-week treatment period refers to leronlimab.

A new trial in the U.S. may also be why they rolled back the enrollment in Brazil

Quote:

---

If approved by the FDA, patients in this trial will be randomized in a 1:1 ratio to receive up to four doses of 700 mg leronlimab with standard of care or placebo with standard of care administered by 30-minute IV infusion weekly over a four-week treatment period.

---